← Back

Entrada Therapeutics Inc

Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a new class of medicines that target intracellular targets previously considered inaccessible. Its Endosomal Escape Vehicle therapeutic candidates are based on a novel therapeutic approach, with a development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases. Preclinical products include ENTR-601-44, ENTR-601-45, and VX-670. The company was formerly known as CycloPorters, Inc., and changed its name to Entrada Therapeutics, Inc. in October 2017. It was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Country
Price · split & dividend adjusted
News & notes moving TRDA
United States
TRDA▼

Entrada Therapeutics reports Q2 net loss of $42.8 million

Entrada Therapeutics reported a second-quarter net loss of $42.8 million, compared to a net loss of $43.1 million in the same quarter of 2025. Collaboration revenue fell to $0.9 million from $2 million a year earlier. As of June 30, 2026, the company held $223 million in cash, cash equivalents, and marketable securities, down from $295.7 million at the end of 2025.
TRDA ▼
TRDA · Capital · Negative Q2 net loss of $42.8 million and declining collaboration revenue, with cash reserves down from $295.7M to $223M.
Read original ↗
Seeking Alpha·60dRead more →
United States
Biotech & Genomic Medicine

Entrada Therapeutics reports second quarter 2026 financial results and pipeline progress

Entrada Therapeutics reported its second quarter 2026 financial results and highlighted upcoming clinical milestones. The company expects to report data from the Cohort 1 open-label period of the ELEVATE-44-201 study by year-end 2026, with Cohort 2 data expected in the first quarter of 2027. Data from Cohort 1 of the ELEVATE-45-201 study is anticipated in October 2026, while Cohort 2 dosing is ongoing at an increased dose of 10 milligrams per kilogram with data expected in the first half of 2027. Vertex is on track to report results from the Phase 1/2 trial of VX-670 in people with myotonic dystrophy type 1 in the second half of 2026. For the second quarter, Entrada posted a net loss of 42.8 million dollars, compared to 43.1 million dollars in the same period last year, and held cash, cash equivalents, and marketable securities of 223.0 million dollars as of June 30, 2026.
TRDA VRTX ▲
Biotech & Genomic Medicine
About megatrends
Biotech & Genomic Medicine › Gene & Cell Editing Technology
TRDA · Capital · Neutral Reports Q2 financial results and pipeline progress; net loss and cash position are routine, with upcoming data readouts.
VRTX · Technology · Positive Vertex's VX-670 trial progress is mentioned as a pipeline milestone, but no results are reported.
Read original ↗
GlobeNewswire·61dRead more →
© 2026 MarketDXAsset